Exchange: STO Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-1.91% SEK277.00
America/New_York / 17 mai 2024 @ 11:29
FUNDAMENTALS | |
---|---|
MarketCap: | 94 143 mill |
EPS: | 6.32 |
P/E: | 43.83 |
Earnings Date: | Jul 15, 2024 |
SharesOutstanding: | 339.87 mill |
Avg Daily Volume: | 0.492 mill |
RATING 2024-05-17 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Buy | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
2.22x |
Company: PE 43.83 | sector: PE 19.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.82x |
Company: PE 43.83 | industry: PE 24.11 |
DISCOUNTED CASH FLOW VALUE |
---|
SEK26.84 (-90.31%) SEK-250.16 |
Date: 2024-05-18 |
Expected Trading Range (DAY) |
---|
SEK 269.29 - 284.71 ( +/- 2.78%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | SEK277.00 (-1.91% ) |
Volume | 0.479 mill |
Avg. Vol. | 0.492 mill |
% of Avg. Vol | 97.41 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.